Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 24,024

Document Document Title
WO/2018/144677A1
Disclosed herein are methods of reducing muscle contraction in a diaphragm or peripheral muscle(s) of a patient sufficient to permit a surgical procedure. The methods may comprise the step of administering an oxime or pharmaceutically ac...  
WO/2018/137483A1
A sustained-release nanoparticle for targeting a neurodegenerative disease, a preparation method thereof, a pharmaceutical composition comprising the same, and a use thereof in preparing a drug for preventing and/or treating a neurodegen...  
WO/2018/140412A1
The present invention describes the use of a 5HT3-antagonist, in combination with neostigmine, to facilitate the treatment of a patient suffering from myasthenia gravis or other myasthenic syndromes by providing a therapeutically effecti...  
WO/2018/138646A1
The present invention relates to a fusion peptide comprising an active peptide portion and a carrier peptide portion. The present invention further relates to the use of such peptide as medicament, particularly for use in the prevention,...  
WO/2018/136943A1
Described herein are compositions comprising activators of TRP and ASIC channels that may be useful to improve or preserve exercise performance and exercise recovery.  
WO/2018/128587A1
Disclosed is an isolated variant of SMCHD1 peptide, or fragment thereof, comprising one or more mutation(s) that increases SMCHD1 activity in a cell compared to a cell with a wild- etype SMCHD1 peptide. Also disclosed are isolated nuclei...  
WO/2018/129395A1
The present invention relates to antibodies, or antigen-binding fragments thereof, that specifically bind proMyostatin and/or latent Myostatin, and methods and uses thereof for treating metabolic diseases.  
WO/2018/129315A1
The invention relates to methods and compositions comprising a TRP channel or ASIC channel activator for preventing or treating a disease, disorder, or condition described herein.  
WO/2018/129434A1
The present invention describes the use of a 5HT3-antagonist, in combination with pyridostigmine, to facilitate the symptomatic treatment of mammalian subjects, and particularly humans, dogs, and cats, suffering from a myasthenic syndrom...  
WO/2018/124292A1
Provided is a method for inducing skeletal muscle cells, the method comprising a step for introducing an MyoD family gene or an expression product thereof, and an Myc family gene or an expression product thereof into mammalian somatic ce...  
WO/2018/120920A1
Disclosed is a cisatracurium besilate lyophilized powder-injection preparation for intravenous administration, which is made of the following components in parts by weight: 1-5 parts of cisatracurium besilate, 10-40 parts of dimyristoylp...  
WO/2018/124011A1
The purpose of the present invention is to provide a motor control function improving agent that improves motor control functions which have deteriorated due to aging or fatigue, and a method for evaluating or selecting the motor control...  
WO/2018/124258A1
The present invention can provide: a prophylactic or ameliorating/therapeutic agent for chronic fatigue syndrome, idiopathic chronic fatigue and fibromyalgia, which contains a processed product of Japanese horseradish (wasabi) as an acti...  
WO/2018/118627A1
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.  
WO/2018/118662A1
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.  
WO/2018/112541A1
The present invention relates to methods of increasing vascular density and/or blood flow in tissue of a subject, and to increasing exercise capacity of a subject, the methods include administering to a subject an effective amount of an ...  
WO/2018/118599A1
Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.  
WO/2018/118957A1
This disclosure provides compositions comprising amino acid entities. The disclosure also provides methods for enhancing muscle function comprising administering an effective amount of the compositions to a subject in need thereof.  
WO/2018/108991A2
The present invention is directed to a method of treating an amyloid-β peptide disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound that enhances mitoc...  
WO/2018/108991A3
The present invention is directed to a method of treating an amyloid-β peptide disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound that enhances mitoc...  
WO/2018/103119A1
The present invention provides a hydrobromate of methyl 3-[(4S)-8-bromo-1-methyl-6-(2-pyridyl)-4H-imidazole[1,2-a][1 ,4]benzodiazepine-4-yl]propionate and related crystal forms and preparation method and use thereof. The hydrobromate has...  
WO/2018/106339A1
Disclosed herein are compositions and methods for use in conjunction with surgical treatments related to tendon repair. Embodiments disclosed herein can locally reduce muscular activity and thereby reduce tension, for example after surgi...  
WO/2018/105550A1
Provided is an amyotrophy inhibiting composition that comprises one or more kinds of peptides as active ingredient(s), said peptides being selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP and ...  
WO/2018/105630A1
The present invention pertains to: a drug for preventing and/or treating cognitive dysfunction and/or a neurodegenerative disease accompanied by accumulation of prionoids, said drug comprising hemagglutinating virus of Japan envelope as ...  
WO/2018/099946A1
The present invention relates to novel bicyclic nucleosides and oligomers prepared therefrom. In particular, the present invention relates to a compound of formula (I), wherein one of T1 and T2 is OR1 or OR2; and the other of T1 and T2 i...  
WO/2018/101398A1
The present invention provides a pharmaceutical composition for use in the treatment or prevention of inflammatory bowel disease (IBD). More particularly, the present invention provides a pharmaceutical composition that contains apelin o...  
WO/2018/096100A1
The present invention provides a new use for cannabinoids in the prevention of pre-cachexia or cachexia in a patient suffering from cancer, wherein said cannabinoid is administered at low dosage and wherein administration is started prio...  
WO/2018/097733A3
A composition for the prevention and/or treatment of chronic fatigue syndrome (CFS)/ myalgia encephalomyelitis (ME) / systemic exertion intolerance disease (SEID) is described. Also described is a method for diagnosis of a patient with c...  
WO/2018/097733A2
A composition for the prevention and/or treatment of chronic fatigue syndrome (CFS)/ myalgia encephalomyelitis (ME) / systemic exertion intolerance disease (SEID) is described. Also described is a method for diagnosis of a patient with c...  
WO/2018/091688A1
The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting i...  
WO/2018/090792A1
Disclosed are a selective Bruton's tyrosine kinase (BTK) inhibitor compound, a pharmaceutical composition, a preparation and the use thereof in the preparation of a drug for treating diseases, disorders or conditions benefiting from the ...  
WO/2018/091691A1
The present invention relates to LSD1 inhibitors and their uses as skeletal muscle hypertrophy inducers as well as to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a diseas...  
WO/2018/091689A1
The present invention relates to skeletal muscle hypertrophy inducers as well as their uses to promote skeletal muscle regeneration, to prevent skeletal muscle atrophy, or in the treatment or prevention of a disease or injury resulting i...  
WO/2018/088501A1
Provided is a method for inducing differentiation of pluripotent stem cells into somatic cells using a medium containing heparin binding growth factor, characterized by comprising contacting starting cells with a conjugate in which a lam...  
WO/2018/083271A1
The present application is concerned with methods for increasing the bioavailability and/or activity of agents and in particular allows selective targeting of an agent to, or via, the liver or allows the liver to be bypassed. By selectin...  
WO/2018/079719A1
The purpose of the invention is to provide a composition that has high biological safety and contributes to the activation of PGC-1α. Also, the purpose of the invention is to provide a use for said composition for activating PGC-1α and...  
WO/2018/078134A1
The present invention relates to compositions and methods for the treatment of myotonic dystrophy.  
WO/2018/077310A1
Disclosed is a vitamin C sodium-containing effervescent tablet, comprising the following components in parts by weight: 200-1120 parts of vitamin C sodium, 560-1300 parts of tartaric acid, 600-1500 parts of sodium bicarbonate, and 200-60...  
WO/2018/079715A1
The purpose of the invention is to provide a composition that has high biological safety and contributes to the inhibition of FOXO1 activity. Also, the purpose of the invention is to provide a use for said composition for inhibiting FOXO...  
WO/2018/076060A1
Methods and compositions for producing mature myotubes are provided herein. In some instances, the method involves contacting a myoblast in an in vitro culture with a compound, wherein the contacting the myoblast in the in vitro culture ...  
WO/2018/076107A1
In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof minocycline, or a functional derivative thereof, and hydroxychloroquine, or a fun...  
WO/2018/078131A1
The present invention relates to compositions and methods for the treatment of myotonic dystrophy.  
WO/2018/076108A1
ABSTRACT In one aspect, there is provided a method of treating, prophylaxis, or amelioration of a neurological disease by administering to a subject in need thereof one or more compounds described herein. In a specific example, the neuro...  
WO/2018/073414A1
The invention concerns the use of Lepista flaccida intended for treating a disease caused by a nonsense mutation of a gene resulting in the premature introduction of a UGA and/or UAA stop codon. It also concerns a Lepista flaccida extrac...  
WO/2018/075858A1
This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, derm...  
WO/2018/070510A1
Provided is an agent developed to be capable of alleviating and suppressing muscle atrophy or muscle mass reduction, even for the elderly and even without requiring exercise, by inducing myogenesis. Provided is a composition for treating...  
WO/2018/066427A1
The present invention addresses the problem of providing a composition for preventing and/or treating neurodegenerative diseases and cerebral infarction and a composition for improving learning disorders. Provided is a composition that c...  
WO/2018/066394A1
Provided is a composition that improves the flexibility of muscles by oral intake. The composition, which makes muscles flexible by oral intake, comprises an n-3 highly unsaturated fatty acid as an active ingredient. The n-3 highly unsat...  
WO/2018/067879A1
In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes ...  
WO/2018/060418A1
The present invention relates to a substance selected from the group comprising irinotecan, an irinotecan active metabolite, 5-fluoro-uracile, a pharmaceutical salt thereof and a mixture thereof, for use in the treatment of fibrosis.  

Matches 1 - 50 out of 24,024